Log In
BCIQ
Print this Print this
 

ethyl icosapentate (MND-21)

  Manage Alerts
Collapse Summary General Information
Company Mochida Pharmaceutical Co. Ltd.
DescriptionOral ethyl icosapentate
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule: Polysaccharide
Latest Stage of DevelopmentPhase II
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH; fatty liver disease)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today